Hyperkalaemia: aetiology, epidemiology, and clinical significance

被引:24
作者
Tromp, Jasper [1 ,2 ,3 ]
van der Meer, Peter [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, AB31,Hanzepl 1, NL-9713 GZ Groningen, Netherlands
[2] Natl Heart Ctr Singapore, Natl Heart Res Inst, 5 Hosp Dr, Singapore 169609, Singapore
[3] Duke NUS Med Sch, 8 Coll Rd, Singapore 169857, Singapore
关键词
Potassium; Hyperkalaemia; Treatment response; Clinical outcomes; CHRONIC HEART-FAILURE; SERUM POTASSIUM LEVELS; SODIUM ZIRCONIUM CYCLOSILICATE; VENTRICULAR SYSTOLIC FUNCTION; CONVERTING-ENZYME INHIBITORS; CHRONIC KIDNEY-DISEASE; EJECTION FRACTION; PREDICTORS; ENALAPRIL; SURVIVAL;
D O I
10.1093/eurheartj/suy028
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Disturbances in the potassium homeostasis are common among patients with heart failure (HF) and negatively affect clinical outcome. Patients with HF have a higher prevalence of common risk factors related to hyperkalaemia, including diabetes mellitus, hypertension, and chronic kidney disease. Furthermore, the use of renin-angiotensin-aldosterone system (RAAS) inhibitors, is an important risk factor for developing hyperkalaemia. The association between hyperkalaemia and mortality is not unequivocal, depends on the study type (trial vs. real-world setting) and is often confounded. More importantly, hyperkalaemia is an important cause of discontinuation or failure to uptitrate to guideline recommended dosages of RAAS inhibitors, which in turn may negatively impact clinical outcomes. The goal of this review is to discuss the epidemiology, aetiology, and clinical consequences of potassium disturbances in HF.
引用
收藏
页码:A6 / A11
页数:6
相关论文
共 46 条
[1]   Associations of serum potassium levels with mortality in chronic heart failure patients [J].
Aldahl, Mette ;
Jensen, Anne-Sofie Caroline ;
Davidsen, Line ;
Eriksen, Matilde Alida ;
Hansen, Steen Moller ;
Nielsen, Berit Jamie ;
Krogager, Maria Lukacs ;
Kober, Lars ;
Torp-Pedersen, Christian ;
Sogaard, Peter .
EUROPEAN HEART JOURNAL, 2017, 38 (38) :2890-2896
[2]   Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial [J].
Anker, Stefan D. ;
Kosiborod, Mikhail ;
Zannad, Faiez ;
Pina, Ileana L. ;
McCullough, Peter A. ;
Filippatos, Gerasimos ;
van der Meer, Peter ;
Ponikowski, Piotr ;
Rasmussen, Henrik S. ;
Lavin, Philip T. ;
Singh, Bhupinder ;
Yang, Alex ;
Deedwania, Prakash .
EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 (10) :1050-1056
[3]   Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF [J].
Beusekamp, Joost C. ;
Tromp, Jasper ;
van der Wal, Haye H. ;
Anker, Stefan D. ;
Cleland, John G. ;
Dickstein, Kenneth ;
Filippatos, Gerasimos ;
van der Harst, Pim ;
Hillege, Hans L. ;
Lang, Chim C. ;
Metra, Marco ;
Ng, Leong L. ;
Ponikowski, Piotr ;
Samani, Nilesh J. ;
van Veldhuisen, Dirk J. ;
Zwinderman, Aeilko H. ;
Rossignol, Patrick ;
Zannad, Faiez ;
Voors, Adriaan A. ;
van der Meer, Peter .
EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 (05) :923-930
[4]   Hypokalemia and Outcomes in Patients With Chronic Heart Failure and Chronic Kidney Disease Findings From Propensity-Matched Studies [J].
Bowling, C. Barrett ;
Pitt, Bertram ;
Ahmed, Mustafa I. ;
Aban, Inmaculada B. ;
Sanders, Paul W. ;
Mujib, Marjan ;
Campbell, Ruth C. ;
Love, Thomas E. ;
Aronow, Wilbert S. ;
Allman, Richard M. ;
Bakris, George L. ;
Ahmed, Ali .
CIRCULATION-HEART FAILURE, 2010, 3 (02) :253-260
[5]   Why are some amyloidoses systemic? Does hepatic "chaperoning at a distance" prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis? [J].
Buxbaum, Joel N. ;
Tagoe, Clement ;
Gallo, Gloria ;
Walker, John R. ;
Kurian, Sunil ;
Salomon, Daniel R. .
FASEB JOURNAL, 2012, 26 (06) :2283-2293
[6]   Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: A retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials [J].
de Denus, Simon ;
Tardif, Jean-Claude ;
White, Michel ;
Bourassa, Martial G. ;
Racine, Normand ;
Levesque, Sylvie ;
Ducharme, Anique .
AMERICAN HEART JOURNAL, 2006, 152 (04) :705-712
[7]   The Substantial Loss of Nephrons in Healthy Human Kidneys with Aging [J].
Denic, Aleksandar ;
Lieske, John C. ;
Chakkera, Harini A. ;
Poggio, Emilio D. ;
Alexander, Mariam P. ;
Singh, Prince ;
Kremers, Walter K. ;
Lerman, Lilach O. ;
Rule, Andrew D. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 28 (01) :313-320
[8]   Incidence and predictors of hyperkalemia in patients with heart failure [J].
Desai, Akshay S. ;
Swedberg, Karl ;
McMurray, John V. ;
Granger, Christopher B. ;
Yusuf, Salim ;
Young, James B. ;
Dunlap, Mark E. ;
Solomon, Scott D. ;
Hainer, James W. ;
Olofsson, Bertil ;
Michelson, Eric L. ;
Pfeffer, Marc A. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (20) :1959-1966
[9]   Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial [J].
Desai, Akshay S. ;
Liu, Jiankang ;
Pfeffer, Marc A. ;
Claggett, Brian ;
Fleg, Jerome ;
Lewis, Eldrin F. ;
McKinlay, Sonja ;
O'Meara, Eileen ;
Shah, Sanjiv J. ;
Sweitzer, Nancy K. ;
Solomon, Scott ;
Pitt, Bertram .
JOURNAL OF CARDIAC FAILURE, 2018, 24 (05) :313-320
[10]   Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril A Secondary Analysis of the PARADIGM-HF Trial [J].
Desai, Akshay S. ;
Vardeny, Orly ;
Claggett, Brian ;
McMurray, John J. V. ;
Packer, Milton ;
Swedberg, Karl ;
Rouleau, Jean L. ;
Zile, Michael R. ;
Lefkowitz, Martin ;
Shi, Victor ;
Solomon, Scott D. .
JAMA CARDIOLOGY, 2017, 2 (01) :79-85